Publication:
Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial.

cris.virtual.author-orcid0000-0002-0006-7833
cris.virtual.author-orcid0000-0002-9094-9476
cris.virtualsource.author-orcid47df8a33-175d-49c2-8a00-6119b3682ac9
cris.virtualsource.author-orcid7aca5059-6bb0-4f79-b445-d436d144bbdc
cris.virtualsource.author-orcid1ef6f073-2d48-43c6-9760-d18b8533c84a
cris.virtualsource.author-orcid717d493b-96db-4872-8921-e96206509da3
cris.virtualsource.author-orcid7cb241ea-c260-4391-899d-77878a27be19
cris.virtualsource.author-orcid96b7370d-d8bf-444f-98ea-132d7a8e824e
cris.virtualsource.author-orcid293ff41f-2638-4ba0-a342-626965287f31
cris.virtualsource.author-orcidcf0b2f7b-e021-4f70-af89-b4cb88c805a2
cris.virtualsource.author-orcid27e66509-69e4-4bbf-ab62-ebd20b6d2e74
datacite.rightsopen.access
dc.contributor.authorKronenberg, Andreas Oskar
dc.contributor.authorBütikofer, Lukas
dc.contributor.authorOdutayo, Ayodele
dc.contributor.authorMühlemann, Kathrin
dc.contributor.authorDa Costa, Bruno
dc.contributor.authorBattaglia, Markus
dc.contributor.authorMeli, Damian
dc.contributor.authorFrey, Peter
dc.contributor.authorLimacher, Andreas
dc.contributor.authorReichenbach, Stephan
dc.contributor.authorJüni, Peter
dc.date.accessioned2024-10-25T13:09:13Z
dc.date.available2024-10-25T13:09:13Z
dc.date.issued2017-11-07
dc.description.abstractObjective To investigate whether symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary tract infection (UTI) in women, thus offering an opportunity to reduce antibiotic use in ambulatory care.Design Randomised, double blind, non-inferiority trial.Setting 17 general practices in Switzerland.Participants 253 women with uncomplicated lower UTI were randomly assigned 1:1 to symptomatic treatment with the NSAID diclofenac (n=133) or antibiotic treatment with norfloxacin (n=120). The randomisation sequence was computer generated, stratified by practice, blocked, and concealed using sealed, sequentially numbered drug containers.Main outcome measures The primary outcome was resolution of symptoms at day 3 (72 hours after randomisation and 12 hours after intake of the last study drug). The prespecified principal secondary outcome was the use of any antibiotic (including norfloxacin and fosfomycin as trial drugs) up to day 30. Analysis was by intention to treat.Results 72/133 (54%) women assigned to diclofenac and 96/120 (80%) assigned to norfloxacin experienced symptom resolution at day 3 (risk difference 27%, 95% confidence interval 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority). The median time until resolution of symptoms was four days in the diclofenac group and two days in the norfloxacin group. A total of 82 (62%) women in the diclofenac group and 118 (98%) in the norfloxacin group used antibiotics up to day 30 (risk difference 37%, 28% to 46%, P<0.001 for superiority). Six women in the diclofenac group (5%) but none in the norfloxacin group received a clinical diagnosis of pyelonephritis (P=0.03).Conclusion Diclofenac is inferior to norfloxacin for symptom relief of UTI and is likely to be associated with an increased risk of pyelonephritis, even though it reduces antibiotic use in women with uncomplicated lower UTI.Trial registration ClinicalTrials.gov NCT01039545.
dc.description.numberOfPages10
dc.description.sponsorshipInstitut für Infektionskrankheiten
dc.description.sponsorshipBerner Institut für Hausarztmedizin (BIHAM)
dc.description.sponsorshipInstitut für Sozial- und Präventivmedizin (ISPM)
dc.description.sponsorshipUniversitätsklinik für Rheumatologie, Immunologie und Allergologie
dc.description.sponsorshipClinical Trials Unit (CTU) Bern
dc.identifier.doi10.7892/boris.106993
dc.identifier.pmid29113968
dc.identifier.publisherDOI10.1136/bmj.j4784
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/155596
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.relation.ispartofBMJ
dc.relation.issn1756-1833
dc.relation.organizationDCD5A442BECFE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BE42E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BDB9E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BAD8E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BD12E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BB13E17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.subject.ddc500 - Science::570 - Life sciences; biology
dc.titleSymptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.startPagej4784
oaire.citation.volume359
oairecerif.author.affiliationInstitut für Infektionskrankheiten
oairecerif.author.affiliationClinical Trials Unit (CTU) Bern
oairecerif.author.affiliationInstitut für Infektionskrankheiten
oairecerif.author.affiliationBerner Institut für Hausarztmedizin (BIHAM)
oairecerif.author.affiliationBerner Institut für Hausarztmedizin (BIHAM)
oairecerif.author.affiliationBerner Institut für Hausarztmedizin (BIHAM)
oairecerif.author.affiliationInstitut für Sozial- und Präventivmedizin (ISPM)
oairecerif.author.affiliationUniversitätsklinik für Rheumatologie, Immunologie und Allergologie
oairecerif.author.affiliationBerner Institut für Hausarztmedizin (BIHAM)
oairecerif.author.affiliation2Universitätsklinik für Infektiologie
oairecerif.author.affiliation2Institut für Sozial- und Präventivmedizin (ISPM)
oairecerif.author.affiliation2Universitätsklinik für Infektiologie
oairecerif.author.affiliation2Clinical Trials Unit Bern (CTU)
oairecerif.author.affiliation2Institut für Sozial- und Präventivmedizin (ISPM)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2019-10-22 21:25:46
unibe.description.ispublishedpub
unibe.eprints.legacyId106993
unibe.journal.abbrevTitleBMJ
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
bmj.j4784.full.pdf
Size:
478.11 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by-nc/4.0
Content:
published

Collections